

Suppl. table 2. Search strategy

Concept for search strategy		
Step 1	<p>Concept 1</p> <p>Th17 pathway inhibitors</p>	<p>Concept 2</p> <p>Psoriatic Arthritis</p>
Step 2	<p>IL17A inhibitors, secukinumab, ixekizumab, IL17R blockers, brodalumab, IL12/23 inhibitors, ustekinumab, IL23 inhibitors, tildrakizumab, guselkumab</p>	<p>psoriatic arthritis, PsA, active psoriatic arthritis, psoriatic arthropathy,</p>
Step 3	<p>#1 = IL17A inhibitors OR secukinumab OR ixekizumab OR IL17R blockers OR brodalumab OR IL12/23 inhibitors OR ustekinumab OR IL23 inhibitors OR tildrakizumab OR guselkumab</p>	<p>#2 psoriatic arthritis OR PsA OR active psoriatic arthritis OR psoriatic arthropathy</p>
Step 4	<p>#1 AND #2</p>	

* Only randomized controlled clinical trials will be considered for inclusion (phase 1 studies are excluded)

Full electronic search strategy for SCOPUS; Limiters: Till November 16th 2016, articles, abstracts or reviews. No language restrictions will be applied.

SCOPUS search terms: (Articles published till 16 NOV 2016)

((TITLE-ABS-KEY (il17a inhibitor*) OR TITLE-ABS-KEY (il17a blocker*) OR TITLE-ABS-KEY (il17r inhibitor*) OR TITLE-ABS-KEY (il17r blocker*) OR TITLE-ABS-KEY (il12/23 inhibitor*) OR TITLE-ABS-KEY (il12/23 blocker*) OR TITLE-ABS-KEY (il23 inhibitor*) OR TITLE-ABS-KEY (il23 blocker*) OR TITLE-ABS-KEY (secukinumab*) OR TITLE-ABS-KEY (ixekizumab*) OR TITLE-ABS-KEY (brodalumab*) OR TITLE-ABS-KEY (ustekinumab*) OR TITLE-ABS-KEY (tildrakizumab*) OR TITLE-ABS-KEY (guselkumab))) AND (ALL (psoriatic arthritis*) OR TITLE-ABS-KEY (psa*) OR TITLE-ABS-KEY (psoriatic arthropathy)) AND ((TITLE-ABS-KEY (trial*)) OR (TITLE-ABS-KEY (random*)) OR (TITLE-ABS-KEY (phase*))))